169 related articles for article (PubMed ID: 23050879)
21. Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas.
Iwamoto FM; Hottinger AF; Karimi S; Riedel E; Dantis J; Jahdi M; Panageas KS; Lassman AB; Abrey LE; Fleisher M; DeAngelis LM; Holland EC; Hormigo A
Neuro Oncol; 2011 Nov; 13(11):1244-51. PubMed ID: 21831900
[TBL] [Abstract][Full Text] [Related]
22. TRIM11 is overexpressed in high-grade gliomas and promotes proliferation, invasion, migration and glial tumor growth.
Di K; Linskey ME; Bota DA
Oncogene; 2013 Oct; 32(42):5038-47. PubMed ID: 23178488
[TBL] [Abstract][Full Text] [Related]
23. Anti-vascular endothelial growth factor receptor (VEGFR) 2 autoantibody identification in glioblastoma patient using single B cell-based antibody gene cloning.
Iizuka A; Komiyama M; Oshita C; Kume A; Ashizawa T; Mitsuya K; Hayashi N; Nakasu Y; Yamaguchi K; Akiyama Y
Immunol Lett; 2014; 159(1-2):15-22. PubMed ID: 24534640
[TBL] [Abstract][Full Text] [Related]
24. Electron-microscopic visualization of binding of antibodies from sera of glioma patients on cultured glioma cells.
Lauro GM; Solheid C; Medolago-Albani L; Di Lorenzo N; Guidetti B
Acta Neuropathol; 1983; 59(2):127-32. PubMed ID: 6837274
[TBL] [Abstract][Full Text] [Related]
25. High serum level of plasminogen activator inhibitor-1 predicts histological grade of intracerebral gliomas.
Iwadate Y; Hayama M; Adachi A; Matsutani T; Nagai Y; Hiwasa T; Saeki N
Anticancer Res; 2008; 28(1B):415-8. PubMed ID: 18383878
[TBL] [Abstract][Full Text] [Related]
26. Expression of emmprin (CD147), a cell surface inducer of matrix metalloproteinases, in normal human brain and gliomas.
Sameshima T; Nabeshima K; Toole BP; Yokogami K; Okada Y; Goya T; Koono M; Wakisaka S
Int J Cancer; 2000 Oct; 88(1):21-7. PubMed ID: 10962435
[TBL] [Abstract][Full Text] [Related]
27. Dynamics of Circulating γδ T Cell Activity in an Immunocompetent Mouse Model of High-Grade Glioma.
Beck BH; Kim H; O'Brien R; Jadus MR; Gillespie GY; Cloud GA; Hoa NT; Langford CP; Lopez RD; Harkins LE; Lamb LS
PLoS One; 2015; 10(5):e0122387. PubMed ID: 25955158
[TBL] [Abstract][Full Text] [Related]
28. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
Chen R; Cohen AL; Colman H
Curr Treat Options Oncol; 2016 Aug; 17(8):42. PubMed ID: 27334978
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model.
Prins RM; Odesa SK; Liau LM
Cancer Res; 2003 Dec; 63(23):8487-91. PubMed ID: 14679014
[TBL] [Abstract][Full Text] [Related]
30. Orthotopic transplantation of v-src-expressing glioma cell lines into immunocompetent mice: establishment of a new transplantable in vivo model for malignant glioma.
Smilowitz HM; Weissenberger J; Weis J; Brown JD; O'Neill RJ; Laissue JA
J Neurosurg; 2007 Apr; 106(4):652-9. PubMed ID: 17432718
[TBL] [Abstract][Full Text] [Related]
31. Identification of tumor-associated autoantigens with SEREX.
Türeci O; Usener D; Schneider S; Sahin U
Methods Mol Med; 2005; 109():137-54. PubMed ID: 15585919
[TBL] [Abstract][Full Text] [Related]
32. Preoperative Neutrophil/Lymphocyte Ratio Is an Independent Prognostic Biomarker in Patients with Low-Grade Gliomas.
Tan Z; Shen L; Wu H; Deng L; Li Z; Huang X
World Neurosurg; 2019 Dec; 132():e585-e590. PubMed ID: 31442642
[TBL] [Abstract][Full Text] [Related]
33. ARID4B is a good biomarker to predict tumour behaviour and decide WHO grades in gliomas and meningiomas.
Tsai WC; Hueng DY; Nieh S; Gao HW
J Clin Pathol; 2017 Feb; 70(2):162-167. PubMed ID: 27451434
[TBL] [Abstract][Full Text] [Related]
34. Targeted transport of 125I-labeled antibody to GFAP and AMVB1 in an experimental rat model of C6 glioma.
Chekhonin VP; Baklaushev VP; Yusubalieva GM; Gurina OI
J Neuroimmune Pharmacol; 2009 Mar; 4(1):28-34. PubMed ID: 18770045
[TBL] [Abstract][Full Text] [Related]
35. Endothelin B receptor expression in malignant gliomas: the perivascular immune escape mechanism of gliomas.
Nakashima S; Sugita Y; Miyoshi H; Arakawa F; Muta H; Ishibashi Y; Niino D; Ohshima K; Terasaki M; Nakamura Y; Morioka M
J Neurooncol; 2016 Mar; 127(1):23-32. PubMed ID: 26645886
[TBL] [Abstract][Full Text] [Related]
36. Antigen related to cell proliferation in malignant gliomas recognized by a human monoclonal antibody.
Kokunai T; Tamaki N; Matsumoto S
J Neurosurg; 1990 Dec; 73(6):901-8. PubMed ID: 2230972
[TBL] [Abstract][Full Text] [Related]
37. Galectin-9: A Predictive Biomarker Negatively Regulating Immune Response in Glioma Patients.
Liang T; Wang X; Wang F; Feng E; You G
World Neurosurg; 2019 Dec; 132():e455-e462. PubMed ID: 31470166
[TBL] [Abstract][Full Text] [Related]
38. Correlation and clinical significance of LC3, CD68+ microglia, CD4+ T lymphocytes, and CD8+ T lymphocytes in gliomas.
Zhang W; Wu S; Guo K; Hu Z; Peng J; Li J
Clin Neurol Neurosurg; 2018 May; 168():167-174. PubMed ID: 29567578
[TBL] [Abstract][Full Text] [Related]
39. Up-regulation of microRNA-15b correlates with unfavorable prognosis and malignant progression of human glioma.
Pang C; Guan Y; Zhao K; Chen L; Bao Y; Cui R; Li G; Wang Y
Int J Clin Exp Pathol; 2015; 8(5):4943-52. PubMed ID: 26191187
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic vaccination against malignant gliomas based on allorecognition and syngeneic tumor antigens: proof of principle in two strains of rat.
Stathopoulos A; Samuelson C; Milbouw G; Hermanne JP; Schijns VE; Chen TC
Vaccine; 2008 Mar; 26(14):1764-72. PubMed ID: 18336964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
